Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQUAMARINE EPA/DHA Study
jRCTs051180125Completed
- Sponsor
- Takeda
- Start
- Aug 2015
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of omega-3-acid triglycerides in coronary arteriosclerosis and hyperlipidemia (3 arms), sponsored by Takeda. Primary endpoint: Change in PMR in primary lesion (CMR). Started Aug 2015; status: completed.
02
Drugs
omega-3-acid triglycerides
03
Conditions
coronary arteriosclerosishyperlipidemia
Beyond the preview
Go deeper on jRCTs051180125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180125.